IP Library Granted Patent US 8,758,747
Granted Patent B2
US 8,758,747 · App. 12/180,794 · Granted Jun 24, 2014

Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies

Inventors: Georg Kallmeyer (Mannheim, DE); Gerhard Winter (Dossenheim, DE); Christian Klessen (Lauterecken, DE); Heinrich Woog (Laudenbach, DE)
Assignee: Roche Diagnostics GmbH
A61K39/395C07K16/00A61K9/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,758,747
App. No.
12/180,794
Granted
Jun 24, 2014
Kind
B2
Abstract

The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilizate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies.

Claims (5)

1. A process for the production of a lyophilized pharmaceutical preparation of monoclonal or polyclonal antibodies, comprising

a) producing an aqueous preparation comprising a monoclonal or polyclonal antibody as the active substance at a concentration up to 20 mg/ml, sucrose in a concentration of 35 mg/ml to 75 mg/ml, an amino acid selected from the group consisting of arginine or ornithine in a concentration of 10 mg/ml to 25 mg/ml and a surfactant selected from the group consisting of Tween 20 (Polyethylene glycol sorbitan monolaurate) and Pluronic F68 (polyoxyethylene-polyoxypropylene polymer) in a concentration of 0.1 mg/ml, and

b) lyophilizing said aqueous preparation.

2. The process according to claim 1 , further comprising pharmaceutical auxiliary substances.

3. The process according to claim 1 , wherein the monoclonal or polyclonal antibody is present in a concentration of 0.25 mg/ml to 8 mg/ml prior to lyophilization.

Priority Claims (1)
EP 96118489 · Nov 19, 1996 · regional
Continuity (2)
Continuation 09308223
Related Publication 20080286280A1 · Nov 20, 2008